At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 4, 2026 at 16:01 ET
Edgewise Therapeutics reported Q3 2026 net income of $1.166 billion ($9.65 diluted EPS), driven by a $1.348 billion gain on the sale of sevasemten to Servier, versus a net loss of $40.7 million a year ago. The company ended the quarter with $1.744 billion in cash and securities, initiated its Phase 2 EQUINOX-HFpEF trial for EDG-15400, and expects to start a Phase 3 trial for EDG-7500 in HCM by year-end 2026. The reported EPS of $9.65 far exceeded the consensus estimate of $2.51, but this reflects a one-time gain, not recurring operations.
- Net income of $1,166.2 million ($9.65 diluted EPS) vs net loss of $40.7 million ($0.39 loss per share) in Q3 2025
- Gain on sevasemten sale of $1.348 billion recognized in Q3 2026
- Cash, cash equivalents and marketable securities of $1,743.9 million as of September 30, 2026
- Phase 3 trial for EDG-7500 in HCM on track to initiate by year-end 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access